1151392-08-3Relevant academic research and scientific papers
BETA-LACTONE COMPOUNDS
-
Page/Page column 28, (2009/05/28)
The present invention provides compounds having the general structure A, or a pharmaceutically acceptable derivatives thereof: wherein R is an alkyl group, and R1 comprises at least one moiety selected from a group consisting of an alkyl, an alkenyl, an aryl, a heterocycle, hydroxyl, ester, amido, aldehyde, and a halogen.
Synthesis of novel &β-lactone inhibitors of fatty acid synthase
Richardson, Robyn D.,Knowles, Lynn M.,Cieplak, Piotr,Smith, Jeffrey W.,Ma, Gil,Oyola, Yatsandra,Zancanella, Manuel,Romo, Daniel
experimental part, p. 5285 - 5296 (2010/04/02)
Fatty acid synthase (FAS) is necessary for growth and survival of tumor cells and is a promising drug target for oncology. Here, we report on the syntheses and activity of novel inhibitors of the thioesterase domain of FAS. Using the structure of orlistat as a starting point, which contains a β-lactone as the central pharmacophore, 28 novel congeners were synthesized and examined. Structural features such as the length of the α- and β-alkyl chains, their chemical composition, and amino ester substitutions were altered and the resulting compounds explored for inhibitory activity toward the thioesterase domain of FAS. Nineteen congeners show improved potency for FAS in biochemical assays relative to orlistat. Three of that subset, including the natural product valilactone, also display an increased potency in inducing tumor cell death and improved solubility compared to orlistat. These findings support the idea that an orlistat congener can be optimized for use in a preclinical drug design and for clinical drug development.
